Publications by authors named "Claire E Barbosa"
Importance: Data on the performance of traumatic brain injury (TBI) biomarkers within minutes of injury are lacking.
Objectives: To examine the performance of glial fibrillary acidic protein (GFAP), ubiquitin carboxy-terminal hydrolase L1 (UCH-L1), and microtubule-associated protein 2 (MAP-2) within 30 and 60 minutes of TBI in identifying intracranial lesions on computed tomography (CT) scan, need for neurosurgical intervention (NSI), and clinically important early outcomes (CIEO).
Design, Setting, And Participants: This cohort study is a biomarker analysis of a multicenter prehospital TBI cohort from the Prehospital Tranexamic Acid Use for TBI clinical trial conducted across 20 centers and 39 emergency medical systems in North America from May 2015 to March 2017.
Article Synopsis
- Tranexamic acid (TXA) is an antifibrinolytic drug effective in reducing mortality from traumatic brain injuries when administered within 2 hours, typically via intravenous (IV) access, which can be challenging to obtain in some settings.
- This study aimed to compare the total drug exposure of TXA administered through intraosseous (IO) access versus IV access in patients with moderate to severe brain injuries, using data from a prehospital trial.
- The results included a cohort of 966 participants, with 345 receiving TXA, showing no significant differences in demographics or renal function between those who received TXA via IO or IV access, indicating that both routes might have similar efficacy for drug exposure.